Cabergoline Effect on Blood Sugar in Type 2 Diabetics

This study is not yet open for participant recruitment.

Verified October 2011 by Mashhad University of Medical Sciences

Sponsor:

Information provided by (Responsible Party):

Haleh Rokni Yazdi, Mashhad University of Medical Sciences

ClinicalTrials.gov Identifier:

NCT01459601

First received: October 24, 2011

Last updated: NA

Last verified: October 2011

History: No changes posted

Tracking Information
First Received Date ^ICMJE	October 24, 2011
Last Updated Date	October 24, 2011
Start Date ^ICMJE	January 2012
Estimated Primary Completion Date	February 2012 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: October 24, 2011)	FBS (fasting blood sugar) [ Time Frame: 30days ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE (submitted: October 24, 2011)	HbA1C [ Time Frame: 30days ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Cabergoline Effect on Blood Sugar in Type 2 Diabetics
Official Title ^ICMJE	Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics
Brief Summary	Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Not Provided
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment
Condition ^ICMJE	Diabetes Type 2
Intervention ^ICMJE	Drug: Cabergoline 0,5mg per week Other Name: Dastinex
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Not yet recruiting
Estimated Enrollment ^ICMJE	10
Estimated Completion Date	February 2012
Estimated Primary Completion Date	February 2012 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Type 2 diabetes HbA1C>7 Exclusion Criteria: HbA1C>10 Psychiatric disorders
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT01459601
Other Study ID Numbers ^ICMJE	CabergolinDM
Has Data Monitoring Committee	No
Responsible Party	Haleh Rokni Yazdi, Mashhad University of Medical Sciences
Study Sponsor ^ICMJE	Mashhad University of Medical Sciences
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Mashhad University of Medical Sciences
Verification Date	October 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top